Ramiro Ribeiro, serving as the Chief Medical Officer at EyePoint, Inc. (NASDAQ:EYPT), has completed the sale of his entire direct equity position in the company. According to a Form 4 filing submitted to the Securities and Exchange Commission, the transaction was executed on June 30, 2026. The executive disposed of 4,875 shares of common stock, generating total proceeds of approximately $73,166.
The shares sold were acquired through the exercise of stock options. These options were exercised at a strike price of $8.26 per share, costing approximately $40,267 in total. The options were part of a vesting schedule that commenced on January 3, 2026, with subsequent vesting occurring monthly over a three-year period. These rights carry an expiration date of January 3, 2035. Following the recent divestiture, Mr. Ribeiro retains no direct common stock ownership in EyePoint but maintains a position of 153,564 stock options.
The sale price per share ranged from $15.00 to $15.06. This execution price sits above the current market valuation of the stock, which trades at $13.98. Market analysis suggests the company may be slightly overvalued at present levels when measured against fair value estimates. Furthermore, data indicates the firm is depleting cash reserves at an accelerated pace, with no analyst forecasts predicting profitability for the current year.
The executive transaction follows a reporting period that saw EyePoint Pharmaceuticals deliver financial results that fell short of market expectations for the first quarter of 2026. The company reported an earnings per share (EPS) of -$0.99, missing the consensus estimate of -$0.82. Revenue also trailed projections, posting $0.7 million compared to the anticipated $1.01 million.
Despite the recent financial miss, analyst sentiment remains divided. Guggenheim has reiterated a Buy rating on the stock, assigning a $68.00 price target. This bullish stance is attributed to progress in clinical trials for therapies targeting wet age-related macular degeneration and diabetic macular edema. The LUGANO and LUCIA trials have successfully completed patient enrollment and are scheduled to release topline data beginning in mid-2026.
Corporate governance developments also occurred during this period. Stockholders approved an amendment to the 2023 Long-Term Incentive Plan, which increased the pool of authorized shares by 4.9 million. Additionally, the company received positive feedback from an independent Data Safety Monitoring Committee, which recommended proceeding with Phase 3 trials for DURAVYU without modifications.
Mizuho has maintained an Outperform rating with a $36.00 price target, citing a competitor's decision to delay a New Drug Application (NDA) submission. The stock has shown recent volatility, closing at $13.98 with a gain of $0.785, or 5.95%, before dipping in after-hours trading to $13.81. These operational and clinical updates reflect the company's continued efforts to advance its pipeline while navigating current financial pressures.